An exploratory meta-analysis of these studies demonstrated that the EGFRvIII mutation in IDH-wt glioblastoma patients is not significantly associated with poorer overall survival (HR = 1.02, p = 0.93) (Figure 4b). Here, IDH1 is linked to glioblastoma.